References
-
1.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):7415-9. [PubMed ID: 6261256]. [PubMed Central ID: PMC350514]. https://doi.org/10.1073/pnas.77.12.7415.
-
2.
Bangham CR, Cook LB, Melamed A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. Semin Cancer Biol. 2014;26:89-98. [PubMed ID: 24316494]. [PubMed Central ID: PMC4062949]. https://doi.org/10.1016/j.semcancer.2013.11.003.
-
3.
Watanabe T. HTLV-1-associated diseases. Int J Hematol. 1997;66(3):257-78. [PubMed ID: 9401272].
-
4.
Kuhnert M, Steuber H, Diederich WE. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir. J Med Chem. 2014;57(14):6266-72. [PubMed ID: 25006983]. https://doi.org/10.1021/jm500402c.
-
5.
Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K. Inhibitory effects of Sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. Phytother Res. 2000;14(7):510-6. https://doi.org/10.1002/1099-1573(200011)14:7<510::aid-ptr646>3.0.co;2-b.
-
6.
Soltani A, Hashemy SI, Zahedi Avval F, Soleimani A, Rafatpanah H, Rezaee SA, et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother. 2019;109:770-8. [PubMed ID: 30551530]. https://doi.org/10.1016/j.biopha.2018.10.139.
-
7.
Satoh T, Li M, Nguyen JT, Kiso Y, Gustchina A, Wlodawer A. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease. J Mol Biol. 2010;401(4):626-41. [PubMed ID: 20600105]. [PubMed Central ID: PMC2918672]. https://doi.org/10.1016/j.jmb.2010.06.052.